Cargando…
Synergistic activity of everolimus and 5‐aza‐2′‐deoxycytidine in medullary thyroid carcinoma cell lines
Medullary thyroid cancer (MTC) is a tumor highly resistant to chemo‐ and radiotherapy. Drug resistance can be induced by epigenetic changes such as aberrant DNA methylation. To overcome drug resistance, we explored a promising approach based on the use of 5‐aza‐2′‐deoxycytidine (AZA), a demethylatin...
Autores principales: | Vitale, Giovanni, Dicitore, Alessandra, Pepe, Daniele, Gentilini, Davide, Grassi, Elisa S., Borghi, Maria O., Gelmini, Giulia, Cantone, Maria C., Gaudenzi, Germano, Misso, Gabriella, Di Blasio, Anna M., Hofland, Leo J., Caraglia, Michele, Persani, Luca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537710/ https://www.ncbi.nlm.nih.gov/pubmed/28453190 http://dx.doi.org/10.1002/1878-0261.12070 |
Ejemplares similares
-
Preclinical Evaluation of Novel Tyrosine-Kinase Inhibitors in Medullary Thyroid Cancer
por: Saronni, Davide, et al.
Publicado: (2022) -
Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model
por: Carra, Silvia, et al.
Publicado: (2021) -
Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study
por: Faggiano, A, et al.
Publicado: (2012) -
Antitumor Activity of Axitinib in Lung Carcinoids: A Preclinical Study
por: Dicitore, Alessandra, et al.
Publicado: (2023) -
Modeling Lung Carcinoids with Zebrafish Tumor Xenograft
por: Carra, Silvia, et al.
Publicado: (2022)